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Abstract Oligonucleotides induce various cellular responses
which are not due to the blockade of protein synthesis by an
antisense mechanism. Oligonucleotides presenting double-
stranded or G-quartet structures (ribo- or deoxyribonucleotides,
phosphodiester or phosphorothioated) induce retraction of
neurites and aggregation of chicken retinal cells within 10^20
h. This effect is reversible, non-toxic; it appears to require
internalization and can be mimicked by treatment of the cells
with an RGDS peptide. The oligonucleotides appear to trigger a
cascade of intracellular events, affecting the adhesive properties
of integrins. In addition, a subset of oligonucleotides induced
platelet aggregation, probably through their interaction with
membrane receptors. Recognition of these effects is important for
the design and interpretation of antisense experiments. ß 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
Key words: Antisense oligonucleotide; Double strand;
Cell aggregation; G-quartet ; Neurite; Platelet
1. Introduction
Antisense oligonucleotides are extremely useful for explor-
ing gene functions [1]. They can be applied to organotypic
cultures and to cultures of primary or transformed cells, under
de¢ned physiological conditions. They can also be used in
vivo, by intravenous injection or even by oral administration
to rats or mice, and for therapeutic purposes in humans [2^4].
Their e¡ect is limited by their metabolic instability, but this
can be circumvented by using stabler derivatives. In addition
to the expected decrease in protein synthesis, antisense oligo-
nucleotides have also been shown to induce responses which
are not related to the targeted gene. For example, it has been
shown that oligonucleotides containing a cluster of guanines
forming a G-quartet structure near their 3P-terminus could
interact with integrins and thus modify the adhesiveness of
cells [5,6]. G-quartet-containing oligonucleotides can also in-
terfere with cell proliferation, probably by interacting with
nucleolin [7,8].
In the course of experiments in which we wished to block
the expression of acetylcholinesterase (AChE) in neural cells
with antisense oligonucleotides, we observed dramatic mor-
phological changes. Although this e¡ect was not produced
by sense and scrambled oligonucleotides used as negative con-
trols, we found that it was not related to AChE synthesis,
because it could be elicited by totally unrelated oligonucleo-
tides. This observation prompted us to investigate this phe-
nomenon and to examine the e¡ects of oligonucleotides on
blood platelets, which do not synthesize proteins. We found
that a subset of oligonucleotides that were active on neural
cells induced a potent platelet aggregation. The e¡ects ob-
served on the two types of cells appear to result from entirely
distinct mechanisms.
We thus report that oligonucleotides can elicit powerful
cellular responses in neural cells and platelets, independently
of any e¡ect on protein synthesis.
2. Materials and methods
2.1. Materials
Human K-thrombin was purchased from Enzyme Research Labo-
ratories and collagen from Nycomed (Nycomed Arzneimittel, Ger-
many). The protein kinase C inhibitor RO 31-8220 was from Calbio-
chem, the src kinase inhibitor pyrazolopyrimidine-type inhibitor 1
(PP-1) and the tyrosine kinase Syk inhibitor piceatannol were from
Biomol (USA). Other reagents were from Sigma.
2.2. Cell cultures
Six-day-old chick embryo neural retinas were dissected and me-
chanically dissociated into a single cell suspension, after mild trypsi-
nization. The cells were suspended in Dulbecco’s modi¢ed Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum, 2% chick-
en serum, 2 mM L-glutamine, 100 000 U/l penicillin/streptomycin, and
0.02 mg/ml gentamicin. Cells (3^5 U105) were seeded in 35-mm tissue
culture plastic dishes pre-coated with a poly-L-lysine solution (100 mg/
ml), and incubated at 37‡C in an atmosphere of 5% CO2 in air.
2.3. Treatment with oligonucleotides
The sequences of oligonucleotides used are given in Table 1. Most
oligonucleotides were custom-synthesized by Genset (Paris, France);
the origins of others are indicated in the table. The oligonucleotides
(0.5^1 WM ¢nal concentration) were added 24 h after plating. Phos-
phodiester oligonucleotides were applied in serum-free DMEM with a
four-fold higher quantity (2^4 WM) of DOTMA (N-[1-(2,3-dioleyl-
oxy)propyl]-N,N,N-trimethylammonium chloride) (lipofectin, Gibco
BRL Life Technologies). Phosphorothioated oligonucleotides were
applied to the cells in aqueous solution.
2.4. Preparation of platelets
Human blood was collected from a forearm vein, and platelet sus-
pensions were prepared as previously described [11]. Aggregation was
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Fig. 1. E¡ect of oligonucleotides on chicken retinal cell cultures. A: Control cells, 48 h after plating on poly-L-lysine-coated dishes. B: Spherical
aggregates induced by a mixture of AChE antisense oligonucleotides A* and J* (Table 1). We obtained similar results when each oligonucleo-
tide was applied separately.
Table 1
Oligonucleotides used in this study
Name Sequence Characteristics E¡ect on
retinal cells
E¡ect on
platelets
A A* AGAGGCGCCATCGCGGGGGGCT antisense against AChE (initiation codon) +++ 3
B B* GTACGGCGGAGGCGCGAGTGCC scrambled, derived from A 3 3
C C* GCATGGGGTACGCGCGGAGCGC derived from A, scrambled +++ n.d.
D* AGAGGTGTTACTGTGGGGGGTC derived from A, exchanging Ts and Cs +++ 3
E* GACCCCCCACAGTAACACCTCT complement of C 3 3
F F* AGAGGCGCCATCGCGGG part of A 3 n.d.
G G* AAGAGAGGCGCCATCGCG antisense, overlapping with A 3 n.d.
H H* AGCCCCCCGCGATGGCGCCTCT sense oligonucleotide, complement of A 3 n.d.
I I* CCCGCGATGGCGCCTCT sense oligonucleotide, complement of F 3 n.d.
J J* GTCCTCCGGGGGACCGGTGGCGTTG antisense against AChE (overlapping exon
2^exon T)
+++ 3
K* CAACGCCACCGGTCCCCCGGAGGAC complement of J 3 3
L* CCTGGGGGAGTATTGCGAAGGAAGG ATP-binding aptamer, containing G-quartets
(DH25.43)
+++ ++
M* CATTGGGGTCCCCCGTGCGGGCGAAGT antisense against AChE (overlapping exons
1^2)
+++ n.d.
N* GGGGTTTGGGGTTTGGGGTTTGGGG G-quartet forming sequence (G4T3) +++ +++
O* GGGTTAGGGTTAGGGTTAGGG human telomeric sequence (G3T2A) +++ 3
P* AGAGGCGCCATCGCGTTATCGCGATGGCGCCTCT hairpin-forming sequence, including part of A +++ 3
Q CAATCGGATCGAATTCGATCCGATTG palindromic sequence, double-stranded hairpin
(ds26)
++ n.d.
R* GAATACGAACTCAATCTCGTAA antisense oligonucleotide, corresponding to
AChE (exon 1)
3 3
S* TTACGAGATTGAGTTCGTATTC sense oligonucleotide, corresponding to
AChE (exon 1)
3 n.d.
T* GAATACGAACTCAATCTCGTAA mixture of two complementary, inactive
oligonucleotides
+++ n.d.
TTACGAGATTGAGTTCGTATTC
U* TCATCCCATTTGCCCAAACCAT antisense oligonucleotide, corresponding to
BChE
3 n.d.
V* ATGGTTTGGGCAAATGGGATGA sense oligonucleotide, corresponding to BChE 3 n.d.
W* TCATCCCATTTGCCCAAACCAT mixture of two complementary, inactive
oligonucleotides
+++ n.d.
ATGGTTTGGGCAAATGGGATGA
X* GTGGCTGTTTGAGAAGGGCAT antisense oligonucleotide, corresponding to
creatine kinase
+ n.d.
Y* ATGCCCTTCTCAAACAGCCAC sense oligonucleotide, corresponding to creatine
kinase
3 n.d.
Z Z poly[(I):poly(C12U) (Ampligene1) imperfect ribonucleotide double-strand +++ n.d.
Most deoxy-oligonucleotides were synthesized and HPLC-puri¢ed by Genset (France). Phosphodiester oligonucleotides are designated A, B, C,
etc., while the corresponding phosphorothioated oligonucleotides are designated A*, B*, C*, etc. In Fig. 3, we used £uorescein-labelled analogs
of oligonucleotides A* and I*. A mixture of complementary ribo-oligonucleotides (Z) was a generous gift from Dr. M.N. Thang. AChE anti-
sense oligonucleotides were designed from the chicken cDNA sequence [9]. N* and O* were shown to form an intramolecular G-quartet [10].
The hairpin oligonucleotide Q (also called ds26) was a gift of Dr. J.-L. Mergny. Oligonucleotides were generally applied to the cells in aqueous
solution. The same e¡ect was obtained with 1 WM phosphorothioated oligonucleotide or 3 WM phosphodiester oligonucleotide, probably due to
the lower stability of the latter in the culture medium and in the cells (note that this concentration is lower than generally used in antisense ex-
periments). The concentration could be reduced in the presence of the cationic lipid DOTMA which forms unilamellar liposomes. Only a subset
of oligonucleotides were tested on platelet aggregation (n.d.: not determined).
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monitored using a Chrono-log dual channel aggregometer with stir-
ring at 900 rpm at 37‡C (5U108 platelets/ml) as described [12].
3. Results and discussion
3.1. Oligonucleotides designed for antisense experiments induce
reversible neurite retraction and aggregation of
chick retinal cells
Dissociated chick retinal cells adhere to polylysine-coated
dishes and extend neurites within 24 h. Upon addition of
antisense phosphodiester oligonucleotides A and J, or phos-
phorothioated oligonucleotides A* and J* (Table 1), directed
against AChE, the cells retract their neurites within 8^10 h
and form spherical aggregates; these changes are complete
after 18 h (Fig. 1). An identical e¡ect is seen with neurons
isolated from the brainstem of 8-day chick embryos (not
shown). After 3^4 days, the cells recover their adherence to
the dish and resume neurite extension (Fig. 2); a second ad-
dition of the same oligonucleotides again induces neurite re-
traction and cell aggregation, and the process can be repeated
a third time (not shown).
Neurite retraction and aggregation appear to involve spe-
ci¢c adhesion molecules, because they do not occur in ¢bro-
nectin-coated dishes, even at a 10-fold higher concentration of
phosphorothioated oligonucleotides (10 WM) (not shown). It
is noteworthy that our cell cultures did not show any sign of
toxic e¡ects under these conditions [2,13].
3.2. The e¡ect is not caused by an antisense mechanism
In experiments done to inactivate AChE expression, the
level of mRNA is reduced to about 30% but AChE activity
remains 70% of the control and the proportions of the di¡er-
ent oligomeric forms of the enzyme [14] are not modi¢ed after
18 h (not shown), a time at which the morphological change is
complete. All types of cells are a¡ected, despite their hetero-
geneity [15]; only about 20% of the cells express AChE (not
shown). Consequently, it does not appear possible to attribute
the morphological changes to suppression of AChE expres-
sion, although they are obtained with antisense oligonucleo-
tides but not with sense or scrambled oligonucleotides. In fact,
a number of oligonucleotides unrelated to AChE also produce
these e¡ects (Table 1).
3.3. Importance of the secondary structure of oligonucleotides
Although antisense and sense oligonucleotides directed
against butyrylcholinesterase (BChE) have no e¡ect when ad-
ministered separately, they induce morphological changes
when applied together (Table 1). This suggests that a dou-
ble-stranded structure may be important. This was con¢rmed
by the fact that self-complementary oligonucleotides (P*, Q)
Fig. 2. Reversibility of morphological changes. A: Control cells, after 2 days in culture (2 D.I.C.). B: Twenty-four hours after plating, the cells
were treated for 24 h with the oligonucleotides (as in Fig. 1). C: Two days after addition of the oligonucleotides (4 D.I.C.). D: At 6 D.I.C.,
the aggregates are £attening. E: At 8 D.I.C., some cells re-extend neurites. F: At 12 D.I.C., most cells are individualized and present extended
neurites. In these experiments, the culture medium was changed every 2^3 days.
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and a mixture of complementary oligonucleotides (T*, W*) or
of synthetic polyribonucleotides, poly(I) and poly(C12U) (Z),
are also e¡ective: thus, the e¡ect appears to be linked to the
secondary structure, but not to the chemical nature of the
oligonucleotides (Table 1).
Some of the AChE antisense oligonucleotides that induced
the e¡ect contained four or ¢ve guanines, suggesting the for-
mation of G-quartet structures [6,16], like the ATP-aptamer
DH25.43 (L*) [17]. It has been reported that a stretch of
guanines at the 3P end of an oligonucleotide can interfere
with cell adhesion [5], but guanines were located at other
positions in some of our most e¡ective oligonucleotides.
3.4. The cellular response requires internalization of the
oligonucleotides and does not involve protein synthesis
Double-stranded RNA complexes elicit a number of cellu-
lar responses, for example during viral infection, including
interferon induction [18]. However, the e¡ect that we observed
in this study could not be transmitted by conditioned medium
(not shown), therefore cannot be ascribed to production of
interferons or other di¡usible factors. Furthermore, they
could not be transmitted by cell-to-cell contacts, since cells
which did not incorporate £uorescent oligonucleotides re-
tained their extended neurites, even though they were in con-
tact with aggregated cells (Fig. 3). Thus, only cells which in-
ternalized oligonucleotides showed the morphological
response. Two other results support this view: (a) the e¡ect
was enhanced by the lipid compound DOTMA, and (b) bio-
tinylated oligonucleotides were active when added to the cul-
ture in soluble form, but not when they were immobilized on
streptavidin-coated dishes prior to addition of the cells (not
shown).
The e¡ect was not suppressed by K-amanitin (0.5 WM) or
cycloheximide (10 WM), applied 2 h before the oligonucleo-
tides (not shown), indicating that it was not related to either
mRNA or protein synthesis.
We cannot entirely exclude the possibility that breakdown
products of the oligonucleotides might participate in the ob-
served e¡ects. However, this appears very unlikely, because
the e¡ect was critically dependent on the sequence, but not
on the phosphodiester or phosphorothioated nature of the
oligonucleotides. The fact that lipofectin facilitated the e¡ect
also indicates that it does not result from an uptake of break-
down products. In addition, the e¡ect was much more rapidly
reversible with oligoribonucleotides (Z), suggesting that the
products of intracellular degradation were inactive.
3.5. Involvement of intracellular calcium stores;
integrin-mediated e¡ects
The oligonucleotide e¡ect was blocked by 1 WM of 8-(N,N-
diethylamino)octyl 3,4,5-trimethoxybenzoate, which prevents
release of intracellular Ca2 stores, by 20 WM thapsigargin,
which inhibits endoplasmic reticulum Ca2-ATPase and de-
pletes Ins(1,4,5)P3-sensitive Ca2 pools, and by preincubation
of the cells with 0.1 mM EGTA for 2 h before addition of the
oligonucleotides (not shown). This suggests that intracellular
Fig. 3. Fluorescent labelling of transfected retinal cells, 3 D.I.C. Only unlabelled cells possess long ¢bers 70 h after oligonucleotide treatment.
A: Fluorescence view of cells transfected with 1 WM £uorescein-labelled oligonucleotide A* without DOTMA (see Section 2). B: Phase contrast
view of the same cells as in A. C: Fluorescence view of cells transfected with 1 WM £uorescein-labelled oligonucleotide A* (Table 1) with lipo-
fectin. D: Phase contrast view of the same cells as in C. Arrows indicate cells which are not £uorescent and extend neurites.
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Ca2 stores are involved. Thus, the oligonucleotides appear to
trigger a cascade of intracellular events involving intracellular
Ca2 stores.
Similar morphological changes were induced by peptides
RGDS and GRGDS but not by RGES, suggesting that they
involve integrin-mediated cell adhesion, probably to vitronec-
tin secreted by the retinal cells themselves. However, the pep-
tides induced more rapidly and more completely reversible
changes than most oligonucleotides and were also e¡ective
on ¢bronectin-coated dishes, leading to a reduction of integrin
a⁄nity for the substrate [19,20]. Although the morphological
changes appear identical, the peptides and oligonucleotides
may act through di¡erent pathways.
3.6. E¡ect of oligonucleotides on platelet aggregation
To con¢rm that oligonucleotides can induce a strong cellu-
lar e¡ect independently of silencing of a speci¢c gene, we
checked their potential e¡ect on human platelets. These
anucleated cells respond rapidly to extracellular stimuli
through ligation of speci¢c membrane receptors, leading to
morphological changes, secretion and aggregation, independ-
ently of protein synthesis. Oligonucleotides D*, J, J*, O* and
P*, which are active on retinal cells, have no e¡ect, but L*
and N* stimulate aggregation of platelets. Aggregation with
oligonucleotide N* is rapid, comparable to that obtained with
1 IU/ml of thrombin, a potent physiological agonist (Fig. 4).
However, platelet activation induced by oligonucleotide N*
is totally blocked by wortmannin, piceatannol or PP-1, in
contrast to activation induced by thrombin, indicating that
they act via distinct intracellular signalling pathways. Activa-
tion by oligonucleotide N* therefore requires phosphoinosi-
tide 3-kinase, a non-receptor tyrosine kinase of the Src family,
as well as tyrosine kinase Syk. This resembles the activation
triggered by membrane receptors such as FcQRIIa [12] and
GpVI [21] (Bernard Payrastre, unpublished observation).
The other oligonucleotides tested do not activate platelets,
except L, which induces a modest aggregation.
4. Conclusion
We show here that half of 26 oligonucleotides tested induce
neurite retraction and formation of globular cell aggregates of
chick retinal cells, and that a subset of these oligonucleotides
trigger aggregation of human platelets. These e¡ects are not
produced via an antisense mechanism, and do not involve
protein synthesis.
Taken together, our observations suggest that the second-
ary structure of the oligonucleotides is important, either as
double-stranded helices or as G-quartets, for inducing cellular
responses. In contrast, the chemical nature of the oligonucleo-
tides appeared irrelevant, since phosphodiester and phospho-
rothioated oligodeoxyribonucleotides, as well as oligoribonu-
cleotides induce the morphological changes. These e¡ects are
independent of chemical toxicity. The e¡ects observed on ret-
inal cells and platelets are probably due to di¡erent mecha-
nisms: the retinal cell response seems to require internaliza-
tion, while platelet activation resembles that induced by
membrane receptors. Further work will be needed to elucidate
the detailed pathways involved in these e¡ects.
However, the immediate importance of the present ¢ndings
is to call attention to the fact that some antisense oligonucleo-
tides, either alone or in combination with their mRNA target,
may induce cellular responses which are not related to sup-
pression of the transcript, at concentrations which are usually
used in antisense experiments. These e¡ects are therefore en-
tirely di¡erent from those obtained with double-stranded
Fig. 4. Aggregation of human blood platelets produced by oligonucleotide N*. Human platelets were preincubated for 10 min either without or
with RO 31-8220 (5 WM), wortmannin (wort., 25 nM), PP-1 (10 WM) or piceatannol (50 WM) and stimulated with oligonucleotide N* (10 Wg/
ml) or thrombin (1 IU/ml). Prostaglandin I2 (PGI2, 10 ng/ml) was preincubated for 2 min before stimulation. The arrows indicate addition of
the agonist. Aggregation was assessed using a Chrono-log dual channel aggregometer with stirring at 900 rpm (5U108 cells/ml). The tracings
are representative of two experiments performed with platelets from di¡erent individuals, which yielded very similar results.
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small interfering RNAs [22,23]. Because of e¡ects such as
those reported here, and in previous studies [24], the design
of antisense experiments and of adequate controls may be
more di⁄cult than is currently realized. On the other hand,
e¡ects such as those illustrated here on neural cells and on
platelets may exist in vivo, upon release of nucleic acid frag-
ments from lytic or apoptotic cells, and could also be of major
clinical relevance.
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